RICHELDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.211
AS - Asia 8.680
EU - Europa 8.560
SA - Sud America 1.214
Continente sconosciuto - Info sul continente non disponibili 221
AF - Africa 196
OC - Oceania 33
Totale 40.115
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.858
GB - Regno Unito 2.774
SG - Singapore 2.660
CN - Cina 2.363
IT - Italia 1.949
HK - Hong Kong 1.013
BR - Brasile 921
VN - Vietnam 865
SE - Svezia 798
FI - Finlandia 600
DE - Germania 599
UA - Ucraina 505
FR - Francia 385
BD - Bangladesh 350
RU - Federazione Russa 349
TR - Turchia 332
KR - Corea 255
IN - India 217
CA - Canada 209
BG - Bulgaria 172
ID - Indonesia 122
NL - Olanda 106
AR - Argentina 89
MX - Messico 79
IQ - Iraq 75
ZA - Sudafrica 69
PK - Pakistan 63
JP - Giappone 56
EC - Ecuador 48
IE - Irlanda 43
ES - Italia 38
PL - Polonia 38
AE - Emirati Arabi Uniti 35
BE - Belgio 35
CO - Colombia 35
AT - Austria 30
UZ - Uzbekistan 30
MY - Malesia 28
CL - Cile 27
VE - Venezuela 25
IR - Iran 24
PY - Paraguay 23
AU - Australia 22
PE - Perù 22
MA - Marocco 21
NG - Nigeria 20
PH - Filippine 20
SA - Arabia Saudita 20
CH - Svizzera 18
TW - Taiwan 17
AL - Albania 16
AZ - Azerbaigian 16
JO - Giordania 16
TH - Thailandia 16
TN - Tunisia 15
CZ - Repubblica Ceca 14
DZ - Algeria 14
EG - Egitto 13
EU - Europa 13
KE - Kenya 13
NP - Nepal 12
LT - Lituania 11
OM - Oman 11
UY - Uruguay 11
CR - Costa Rica 10
IL - Israele 10
JM - Giamaica 10
BO - Bolivia 9
HN - Honduras 9
DK - Danimarca 8
SN - Senegal 8
LB - Libano 7
PT - Portogallo 7
RO - Romania 7
BH - Bahrain 6
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
LV - Lettonia 6
MD - Moldavia 6
PS - Palestinian Territory 6
RS - Serbia 6
AM - Armenia 5
DO - Repubblica Dominicana 5
EE - Estonia 5
FJ - Figi 5
GT - Guatemala 5
KG - Kirghizistan 5
NO - Norvegia 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
NI - Nicaragua 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BY - Bielorussia 3
GE - Georgia 3
KZ - Kazakistan 3
Totale 39.853
Salva come PNG Salva come JPEG
Città #
Fairfield 2.180
Southend 2.014
Ashburn 1.933
Santa Clara 1.714
Singapore 1.697
Woodbridge 1.472
Houston 1.147
Hong Kong 981
Jacksonville 964
Chandler 921
Seattle 823
Hefei 804
Dearborn 752
Wilmington 726
Ann Arbor 696
Cambridge 692
San Jose 636
Beijing 454
Nyköping 452
Helsinki 426
London 411
Los Angeles 327
Chicago 317
Council Bluffs 301
The Dalles 272
Ho Chi Minh City 254
New York 247
Hanoi 217
Seoul 198
San Diego 195
Modena 192
Milan 179
Princeton 172
Sofia 165
Eugene 158
Lauterbourg 140
Salt Lake City 137
Buffalo 132
Izmir 125
Dallas 94
Shanghai 91
Rome 87
Moscow 83
Naples 74
Jakarta 73
Phoenix 70
São Paulo 66
Columbus 65
Des Moines 64
Tampa 62
Toronto 58
Frankfurt am Main 53
Palermo 53
Redwood City 49
Bremen 46
Atlanta 43
Da Nang 43
Elk Grove Village 43
Haiphong 43
Orem 43
Montreal 42
Dublin 40
Boardman 35
Florence 35
Guangzhou 35
Tokyo 34
Brussels 33
Turin 33
Chennai 32
North Bergen 32
Sterling 32
Bologna 30
San Francisco 30
Bari 29
Norwalk 29
Tashkent 29
Jersey City 28
Warsaw 28
Miano 27
Mumbai 27
Dong Ket 26
Brooklyn 25
Lahore 25
Philadelphia 24
Boston 23
Detroit 23
Munich 23
Rio de Janeiro 23
Baghdad 22
Denver 22
Kunming 22
Lancaster 21
Mexico City 21
Miami 21
Amsterdam 20
Kent 20
Belo Horizonte 19
Changsha 19
Falls Church 19
San Mateo 19
Totale 28.003
Salva come PNG Salva come JPEG
Nome #
Malattie infiltrative diffuse del polmone 1.228
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 807
Non-steroid agents for idiopathic pulmonary fibrosis 474
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 459
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 455
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 443
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 424
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 409
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 404
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 399
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 380
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 363
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 363
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 363
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management 360
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 357
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 356
Aortic pulse wave velocity measurement in systemic sclerosis patients. 343
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 342
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 335
Emerging drugs for idiopathic pulmonary fibrosis. 334
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 329
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 323
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 323
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 323
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 322
Management of idiopathic pulmonary fibrosis. 320
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 317
Rifabutin for treating pulmonary tuberculosis. 314
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 310
Macrolides in the treatment of asthma and cystic fibrosis 306
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 306
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 305
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 300
Early diagnosis of subclinical multi drug-resistant tuberculosis 298
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis 298
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 298
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 297
An update on the diagnosis of tuberculosis infection 295
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 295
Novel drug targets for idiopathic pulmonary fibrosis 295
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection 293
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 293
Pulmonary fibrosis and the many faces of UIP 293
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 293
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 290
Management of Idiopathic Pulmonary Fibrosis 289
Sarcoidosis: challenging diagnostic aspects of an old disease. 288
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 288
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 287
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 286
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 285
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis 283
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 279
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 279
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 275
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 273
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 270
Prevalence and prognosis of unclassifiable interstitial lung disease 267
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 266
Smoking-related interstitial lung disease 260
Blood tests for diagnosis of tuberculosis - Reply 255
Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy 254
Mycobacterium tuberculosis induces CCL18 expression in human macrophages 253
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 248
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 247
The big clinical trials in idiopathic pulmonary fibrosis. 246
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 245
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 245
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 245
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 244
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 244
Macrolides for chronic asthma. 242
Analysis of sputum in COPD 239
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 238
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 237
L'infezione tubercolare nel bambino: il contributo dei nuovi test immunologici 235
The complex interrelationships between chronic lung and liver disease: a review. 233
Challenges in idiopathic interstitial lung disease 233
Immunomodulatory agents for idiopathic pulmonary fibrosis. 231
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 231
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 231
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 230
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 229
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 229
ANTIBODY REPERTOIRE AGAINST THE A60 ANTIGEN COMPLEX DURING THE COURSE OF PULMONARY TUBERCULOSIS 226
Tubercolosi 225
Co-trimoxazole effect on human alveolar macrophages of AIDS patients 225
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. 223
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 222
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 218
Interaction of genetic and exposure factors in the prevalence of berylliosis 215
Genetic testing in diffuse parenchymal lung disease 212
First report of the Italian register for diffuse infiltrative lung disorders (RIPID) 211
Interferon gamma assays for tuberculosis 210
The role of biomarkers in low respiratory tract infections. 209
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. 207
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 207
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 207
Tuberculosis diagnostic tests: Sensitivity, specificity, and comparing apples with apples 205
Totale 30.195
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 148.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.903 86 488 275 221 59 87 200 108 293 208 525 353
2022/20232.694 324 274 169 241 317 402 47 292 331 81 116 100
2023/20242.023 62 129 124 173 372 244 245 244 67 47 128 188
2024/20255.889 212 90 84 417 1.236 847 389 367 631 357 585 674
2025/202612.119 676 489 1.084 1.283 1.747 1.035 1.538 649 1.153 964 883 618
2026/2027487 487 0 0 0 0 0 0 0 0 0 0 0
Totale 40.115